Research

At CREST.BD, we undertake action-oriented research with a high potential for impact on the health, quality of life and care of people with bipolar disorder.

We create and advance knowledge and understanding of bipolar disorder to contribute to optimal health and quality of life through the discovery, dissemination and application of research.

CREST CURRENTS NEWSLETTER

Stay up to date with research and knowledge exchange on bipolar disorder.

Effectiveness of lurasidone in improving cognitive function in bipolar patients

This study is looking at changes in cognitive function in bipolar patients who are treated with 20 to 80mg/day of Lurasidone vs Placebo adjunctive therapy over a 6 week period.



ELICE-BD Lurasidone and Bipolar Disorder study

WHO CAN PARTICIPATE?

  • Males and females between 19-65 years of age
  • Have a diagnosis of Bipolar Disorder
  • Are clinically stable on current medication
  • Not currently in a manic or depressed episode

WHAT IS INVOLVED?
The study involves a screening visit, baseline visit, clinical visits at Weeks 3 and 6, and 4 telephone calls at Week 1, 2, 4 and 2 weeks after last visit. Participants will complete neurocognitive (eg: memory, reasoning and attention) testing and give blood samples. Participants with cognitive impairment will be randomly allocated, to either receive lurasidone or placebo added to their current medications for 6 weeks.

STUDY LOCATION
Outpatient Clinic, Mood Disorders Centre, Djavad Mowafaghian Centre for Brain Health at UBC
Vancouver, BC, Canada (Google Maps)

CONTACT INFORMATION / SIGN UP:
Jayasree Basivireddy, Clinical Research Coordinator
Phone: 604.822.3769
Email: jayasree.basivireddy@ubc.ca

PRINCIPAL INVESTIGATOR
Dr. Lakshmi N Yatham
Professor, Department of Psychiatry, Faculty of Medicine, UBC;
Regional Head of Psychiatry and Regional Program Medical Director,
Vancouver Coastal Health & Providence Healthcare

MORE INFO: https://www.vchri.ca/research-study/study-efficacy-lurasidone-cognitive-functioning-bipolar-patients-elicebd

This study will conclude in December 2025.

Back to Participate in Research